NasdaqCM - Delayed Quote • USD
ARCA biopharma, Inc. (ABIO)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 4:57 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Thomas A. Keuer | President, COO & Principal Executive Officer | 400.8k | -- | 1959 |
Mr. C. Jeffrey Dekker CPA | CFO, Treasurer & Company Secretary | 323.07k | -- | 1965 |
ARCA biopharma, Inc.
10170 Church Ranch Way
Suite 100
Westminster, CO 80021
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 4
Description
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Corporate Governance
ARCA biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 25, 202410-Q: Periodic Financial ReportsSee Full Filing
- Apr 23, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 11, 2024SC 13G: Tender Offer/Acquisition ReportsSee Full Filing
- Apr 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 03, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Apr 25, 2024
ARCA biopharma, Inc. Earnings Call
Related Tickers
KTRA Kintara Therapeutics, Inc.
0.1580
+15.08%
PHIO Phio Pharmaceuticals Corp.
0.7060
+5.22%
LGVN Longeveron Inc.
1.6700
-2.91%
CLNN Clene Inc.
0.3465
+2.82%
JAGX Jaguar Health, Inc.
0.1700
+0.06%
PXMD PaxMedica, Inc.
0.7042
+1.76%
CADL Candel Therapeutics, Inc.
6.43
+6.28%
NKGN NKGen Biotech, Inc.
1.9800
+15.79%
ACRV Acrivon Therapeutics, Inc.
8.47
-10.84%
GRTX Galera Therapeutics, Inc.
0.2075
+13.57%